Bionano Genomics, INC Schedule 13G passive stakes

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a beneficial ownership of 9.9% in Bionano Genomics, Inc. through warrant exercises.

CVI Investments and Heights Capital Management have disclosed a 9.9% beneficial ownership stake in Bionano Genomics, primarily through warrants.

Lind Global Fund III LP and its affiliates have reported a 9.9% beneficial ownership stake in Bionano Genomics, Inc., primarily through exercisable warrants.

Iroquois Capital Management, LLC, Richard Abbe, and Kimberly Page have filed an amended Schedule 13G disclosing their beneficial ownership in BriaCell Therapeutics Corp., including warrants subject to a 4.99% ownership blocker.

Iroquois Capital Management, LLC, along with Richard Abbe and Kimberly Page, reported a 4.99% beneficial ownership stake in Bionano Genomics, Inc., including shares from warrants subject to ownership blockers.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 9.99% beneficial ownership stake in Bionano Genomics, Inc., primarily through warrants and a convertible note.

Lind Global Fund III LP and affiliates reported a 9.9% beneficial ownership stake in Bionano Genomics, Inc., comprising common stock and warrants.

CVI Investments, managed by Heights Capital Management, disclosed a 9.9% beneficial ownership stake in Bionano Genomics, Inc. common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a passive beneficial ownership of 4.99% in Bionano Genomics, Inc. common stock.

Iroquois Capital Management and its principals, Richard Abbe and Kimberly Page, reported a combined 5.4% beneficial ownership in Bionano Genomics, Inc. common stock.

Lincoln Alternative Strategies LLC has reported a passive beneficial ownership of 5.42% in Bionano Genomics, Inc., holding 525,000 shares of common stock.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.9% in Bionano Genomics, Inc. as of March 31, 2025.

CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., have jointly disclosed a beneficial ownership of 7.7% of Bionano Genomics, Inc.'s common stock, totaling 10.7 million shares.